- CMTA and Pharnext Enter Biomarker Research CollaborationCollaboration focused on identifying and characterizing key biomarkers in Charcot-Marie-Tooth disease Type 1ARead more ...
- Craig Zeltsar Joins CMTA Board of DirectorsThe Charcot-Marie-Tooth Association today welcomed Craig Zeltsar, principal and co-founder of NNE Marketing, LLC, to its Board of Directors.Read more ...
- Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth DiseaseACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo; Acceleron to discontinue development of ACE-083.Read more ...
- David Coldiron Joins CMTA Board of DirectorsThe Charcot-Marie-Tooth Association (CMTA), the national patient advocacy organization leading CMT research, today announced the appointment of David Coldiron to its Board of Directors.Read more ...
- New Gene Therapy Development Program for CMT2APassage Bio, a genetic medicines company developing AAV-delivered gene therapies, today announced a gene therapy development program for Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).Read more ...